Compounds for use as antidepressants, aphrodisiacs and adjunctive therapies in humans

• US 6,667,308 B2
• Filed: 04/13/2001
• Issued: 12/23/2003
• Est. Priority Date: 04/13/2000
• Status: Expired due to Term

• Current Assignee: Savanna Health, LLC
• Original Assignee: Seroctin Research & Technologies
• Inventors: Rosenfeld, Mark J., Negus, Norman C., Berger, Patricia J.
• Primary Examiner(s): Ford, John M.
• Application Number:
  US09/834,592
• Publication Number:
  US 20010053789A1
• Time in Patent Office: 984 Days
• Field of Search: 514/375, 514/376, 514/230.5, 548/221, 548/217
• US Class Current: 514/230.5
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: C07D 263/58 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• CPC Class Codes: C07D 265/36 condensed with one six-membered ring

Abstract

Phenolic compounds with a phenolic molecule to which are covalently linked an oxygen-containing group, a nitrogen- or another oxygen containing group, and a C₁-C₄ alkoxy group, obtainable from monocotyledonous plants, animals that eat such plants, or chemical synthesis, have been found to act as an antidepressant or otherwise a treatment for bettering mood, a therapy for improving sexual desire or performance, an adjunctive therapy for achieving weight loss, and an adjunctive therapy for substance abuse and addiction. These compounds, at concentrations suitable for human therapeutic use, may be obtained from plants such as corn in their early growth stages and from parts of animals such as the velvet antler tips of deer and elk.

Claims

1. A process for treating sexual desire, arousal and performance in humans by the administration of a therapeutically effective amount of one or more chemical compositions defined as:

Wherein “

R”

represents C₁-C₄ alkoxy, with the provision the R is in the 4 or 5 ring position;

Wherein “

n”

represents one of the integers 0, 1 or 2;

Wherein “

B”

represents H and “

A”

represents —

OH, —

NH₂ or NHCR′

, where R′

denotes C₁-C₄ alkyl; and

“

B A”

represents

or pharmaceutically acceptable salts thereof.

2. A process according to claim 1, wherein at least one of the chemical compositions is defined as:

Wherein “

R”

represents C₁-C₄ alkoxy, with stipulation that R is in the 4 or 5 ring position;

Wherein “

n”

represents one of the integers 0, 1 or 2;

or pharmaceutically acceptable salts thereof.

3. A process according to claim 1, wherein at least one of the chemical compositions is obtained from one or more monocotyledonous plants selected from the group consisting of corn, wheat, barley, rye, oats, rice, sorghum, millet, bamboo, barley-like grasses, and wild grasses, by growing the plant to an immature life history stage, harvesting the plant, and drying the harvested plant.

4. A process according to claim 3, wherein the harvested plant is dried at a temperature in the range of 40°

C. to 45°

C.

5. A process according to claim 3, wherein the dried harvested plant contains combined amounts of 4-hydroxycinnamic acid and 4-hydroxy-3-methoxycinnamic acid totaling no more than 1.5 mg/gm (dry weight).

6. A process according to claim 3, wherein the harvested plant is immature corn.

7. A process according to claim 6, wherein the immature corn has been grown to a height that does not exceed 30-45 centimeters.

8. A process according to claim 6, wherein the immature corn has been grown for no more than five weeks after planting.

9. A process according to claim 1, wherein the administered chemical composition comprises a daily dosage of 15 mg.

10. A process according to claim 1, wherein the dried harvested plant contains phenols in total amounts greater than 17.0 mg/gm (dry weight).

11. A process according to claim 10, wherein the dried harvested plant contains combined amounts of 4-hydroxycinnamic acid and 4-hydroxy-3-methoxycinnamic acid totaling no more than 1.5 mg/gm (dry weight).

12. A process according to claim 10, wherein the harvested plant is immature corn, Zea Mays.

13. A process according to claim 12, wherein the immature corn has been grown to a height that does not exceed 30-45 centimeters.

14. A process according to claim 10, wherein the immature corn has been grown for no more than five weeks after planting.

15. A process according to claim 1, wherein said chemical composition is administered in a manner selected from the group consisting of:

(1) orally, in the form of tablets, capsules, suspensions, solutions and other means suitable for ingestion;

(2) parenteral injection, in the form of subcutaneous, intramuscular, intravenous;

(3) implant for sustained release; and

(4) transdermal patch.

18. A process according to claim 15, wherein at least one of the chemical compositions is obtained from one or more monocotyledonous plants selected from the group consisting of corn, wheat, barley, rye, oats, rice, sorghum, millet, bamboo, barley-like grasses, and wild grasses, by growing the plant to an immature life history stage, harvesting the plant, and drying the harvested plant.

19. A process according to claim 18, wherein the harvested plant is dried at a temperature in the rage of 40°

C. to 45°

C.

20. A process according to claim 18, wherein the dried harvested plant contains phenols in total amounts greater than 17.0 mg/gm (dry weight).

21. A process according to claim 18, wherein the dried harvested plant contains combined amounts of 4-hydroxycinnamic acid and 4-hydroxy-3-methoxycinnamic acid totaling no more than 1.5 mg/gm (dry weight).

22. A process according to claim 18, wherein the harvested plant is immature corn.

23. A process according to claim 22, wherein the dried immature corn contains phenols in total amounts greater than 17.0 mg/gm (dry weight).

24. A process according to claim 22, wherein the dried immature corn contains combined amounts of 4-hydroxycinnamic acid and 4-hydroxy-3-methoxycinnamic acid totaling no more than 1.5 mg/gm (dry weight).

25. A process according to claim 22, wherein the immature corn is Zea Mays.

26. A process according to claim 22, wherein the immature corn has been grown to a height that does not exceed 30-45 centimeters.

27. A process according to claim 22, wherein the immature corn has been grown for no more than five weeks after planting.

28. A process according to claim 18, wherein the harvested plant has been grown to a height that does not exceed 30-45 centimeters.

29. A process according to claim 18, wherein the harvested plant has been grown for no more than five weeks after planting.

16. A process for treating depression in humans by the administration of a therapeutically effective amount of one or more chemical compositions defined as:

Wherein “

R”

represents C₁-C₄ alkoxy, with the provision the R is in the 4 or 5 ring position;

Wherein “

n”

represents one of the integers 0, 1 or 2;

Wherein “

B”

represents H and “

A”

represents —

OH, —

NH₂ or NHCR′

, where R′

denotes C₁-C₄ alkyl; and

“

B A”

represents

or pharmaceutically acceptable salts thereof.

17. A process according to claim 16, wherein the administered chemical composition comprises a daily dosage of 15 mg.

30. A process according to claim 16, wherein said chemical composition is administered in a manner selected from the group consisting of:

(1) orally, in the form of tablets, capsules, suspensions, solutions and other means suitable for ingestion;

(2) parenteral injection, in the form of subcutaneous, intramuscular, intravenous;

(3) implant for sustained release; and

(4) transdermal patch.

31. A process for treating sexual desire, arousal and performance in humans by the administration of a therapeutically effective amount of one or more chemical compositions defined as:

Wherein “

R”

represents C₁-C₄ alkoxy, with stipulation that R is in the 4 or 5 ring position;

Wherein “

n”

represents one of the integers 0, 1 or 2;

or pharmaceutically acceptable salts thereof.

32. A process according to claim 31, wherein one of said chemical compositions comprise 6-methoxy-2,3-benzoxazolinone defined as:

or pharmaceutically acceptable salts thereof.

33. A process according to claim 31, wherein the administered chemical composition comprises a daily dosage of 15 mg.

34. A process according to claim 31, wherein at least one of the chemical compositions is obtained from one or more monocotyledonous plants selected from the group consisting of corn, wheat, barley, rye, oats, rice, sorghum, millet, bamboo, barley-like grasses, and wild grasses, by growing the plant to an immature life history stage, harvesting the plant, and drying the harvested plant.

35. A process according to claim 34, wherein the dried harvested plant contains phenols in total amounts greater than 17.0 mg/gm (dry weight).

36. A process according to claim 34, wherein the dried harvested plant contains combined amounts of 4-hydroxycinnamic acid and 4-hydroxy-3-methoxycinnamic acid totaling no more than 1.5 mg/gm (dry weight).

37. A process according to claim 34, wherein the harvested plant is immature corn, Zea Mays.

38. A process according to claim 37, wherein the immature corn has been grown to a height that does not exceed 30-45 centimeters.

39. A process according to claim 37, wherein the immature corn has been grown for no more than five weeks after planting.

40. A process according to claim 34, wherein the harvested plant is dried at a temperature in the rage of 40°

C. to 45°

C.

41. A process according to claim 31, wherein said chemical composition is administered in a manner selected from the group consisting of:

(1) orally, in the form of tablets, capsules, suspensions, solutions and other means suitable for ingestion;

(2) parenteral injection, in the form of subcutaneous, intramuscular, intravenous;

(3) implant for sustained release; and

(4) transdermal patch.

42. A process for treating mood disorders in humans by the administration of a therapeutically effective amount of one or more chemical compositions defined as:

Wherein “

R”

represents C₁-C₄ alkoxy, with stipulation that R is in the 4 or 5 ring position;

Wherein “

n”

represents one of the integers 0, 1 or 2;

or pharmaceutically acceptable salts thereof.

43. A process according to claim 42, wherein one of said chemical compositions comprise 6-methoxy-2,3-benzoxazolinone defined as:

or pharmaceutically acceptable salts thereof.

44. A process according to claim 42, wherein the administered chemical composition comprises a daily dosage of 15 mg.

45. A process according to claim 42, wherein at least one of the chemical compositions is obtained from one or more monocotyledonous plants selected from the group consisting of corn, wheat, barley, rye, oats, rice, sorghum, millet, bamboo, barley-like grasses, and wild grasses, by growing the plant to an immature life history stage, harvesting the plant, and drying the harvested plant.

46. A process according to claim 45, wherein the harvested plant is dried at a temperature in the rage of 40°

C. to 45°

C.

47. A process according to claim 45, wherein the dried harvested plant contains phenols in total amounts greater than 17.0 mg/gm (dry weight).

48. A process according to claim 45, wherein the dried harvested plant contains combined amounts of 4-hydroxycinnamic acid and 4-hydroxy-3-methoxycinnamic acid totaling no more than 1.5 mg/gm (dry weight).

49. A process according to claim 45, wherein the harvested plant is immature corn, Zea Mays.

50. A process according to claim 49, wherein the immature corn has been grown to a height that does not exceed 30-45 centimeters.

51. A process according to claim 49, wherein the immature corn has been grown for no more than five weeks after planting.

52. A process according to claim 42, wherein said chemical composition is administered in a manner selected from the group consisting of:

(1) orally, in the form of tablets, capsules, suspensions, solutions and other means suitable for ingestion;

(2) parenteral injection, in the form of subcutaneous, intramuscular, intravenous;

(3) implant for sustained release; and

(4) transdermal patch.